Compare LCID & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCID | KNSA |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.5B |
| IPO Year | 2020 | 2018 |
| Metric | LCID | KNSA |
|---|---|---|
| Price | $9.91 | $48.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $19.67 | ★ $55.29 |
| AVG Volume (30 Days) | ★ 5.0M | 539.0K |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.75 |
| Revenue | $595,271,000.00 | ★ $677,564,000.00 |
| Revenue This Year | $70.41 | $38.01 |
| Revenue Next Year | $92.93 | $17.42 |
| P/E Ratio | ★ N/A | $65.09 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $1.97 | $18.26 |
| 52 Week High | $25.22 | $49.33 |
| Indicator | LCID | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 62.30 |
| Support Level | $9.38 | $41.55 |
| Resistance Level | $10.82 | N/A |
| Average True Range (ATR) | 0.49 | 1.66 |
| MACD | -0.03 | 0.20 |
| Stochastic Oscillator | 48.63 | 89.75 |
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations and through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.